I’m sorry, but effective precedents for cost control don’t exist in the US, which is a hill Pharma will die on.
The most effective policy interventions for bending the cost curve on IP-protected treatments exist, but in the UK and Netherlands and even Thailand - in the form of public authorities like NICE which negotiate on prices based on a rational assessment of their relative benefit to population health rather than saddling that on sick patients.
The answer is there, it’s just politicised as nonsense about “death panels” when most Americans actually already face this every time they get to the hospital and have a bill they can’t pay, including for insulin
7j7j21 karma
I’m sorry, but effective precedents for cost control don’t exist in the US, which is a hill Pharma will die on. The most effective policy interventions for bending the cost curve on IP-protected treatments exist, but in the UK and Netherlands and even Thailand - in the form of public authorities like NICE which negotiate on prices based on a rational assessment of their relative benefit to population health rather than saddling that on sick patients.
The answer is there, it’s just politicised as nonsense about “death panels” when most Americans actually already face this every time they get to the hospital and have a bill they can’t pay, including for insulin
View HistoryShare Link